TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05958056

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance exercise
Description: The training session included leg curl and leg extension exercises with 4 sets each. Participants started with leg extension exercise for 4 sets with a 30-second rest periods between the sets. Then, participants took a rest for 60 seconds. Afterward, participants performed leg curl exercise for 4 sets with a 30-second rest periods between the sets. Exercises in each set were performed continuously (uninterrupted) with a speed of 2 seconds for each repetition and a medium exercise performance speed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: The training session included leg curl and leg extension exercises with 4 sets each. Participants started with leg extension exercise for 4 sets with a 30-second rest periods between the sets. Then, participants took a rest for 60 seconds. Afterward, participants performed leg curl exercise for 4 sets with a 30-second rest periods between the sets. Exercises in each set were performed continuously (uninterrupted) with a speed of 2 seconds for each repetition and a medium exercise performance speed.
Study: NCT06710158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC-102
Description: SC-102 is a peptide drug conjugate (PDC) consisting an EphA2-targeting peptide, a tubulin inhibitor, and a protease-hydrolyzable linker.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC-102
Description: SC-102 is a peptide drug conjugate (PDC) consisting an EphA2-targeting peptide, a tubulin inhibitor, and a protease-hydrolyzable linker.
Study: NCT06710444

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound-guided erector spinae plane block
Description: ESPB

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound-guided retrolaminar plane block
Description: RLB
Study: NCT06708364

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Training
Description: Virtual reality training (X-BOX). Table tennis~* Frequency: 3 day per week~* Intensity: Mild to moderate as per Game. Exer-game ( River Rush)~* Time: total 30 minute of training with 5 min warm and 5 min cool down.~* Type: aerobic exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cycle Ergometer
Description: * Frequency: 3 days per week.~* Intensity: 40-60% of HRR~* Time: total 30 minutes with 5 min warm up and 5 min cool down~* Type: aerobic exercise
Study: NCT06708715

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PEACE Patch
Description: A topical patch that incorporates a sensory pattern of vibrotactile haptic technology.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Topical Sham Patch
Description: Sham Patch that does not include vibrotactile haptic technology
Study: NCT06707779

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF with electrical stimulation
Description: Group A receive PNF including combination of isotonic and rhythmic stabilization on trunk with electrical stimulation Participants perform three sets10 repetitions at maximal resistance The resting interval of 30 seconds and 60 seconds will be provided after the completion of 10 repetitions for each pattern and between sets respectively.~In total all PNF exercise will be held for 30 to 45 minutes. 'BURST' TENS (acupuncture-like TENS), characterized by discontinuous stimulation at low frequencies (1-4 Hz), with wave durations of 100-400 ms and high intensities, inducing weak muscle twitches for 10 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF without electrical stimulation
Description: Group B receive PNF including combination of isotonic and rhythmic stabilization on trunk without electrical stimulation. Participants perform three sets of 10 repetitions at maximal resistance will be provided by the same physiotherapist.~The resting interval of 30 seconds and 60 seconds will be provided after the completion of 10 repetitions for each pattern and between sets respectively.~In total all PNF exercise will be held for 30 to 45 minutes.
Study: NCT06709092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lupatadine fumarate (Luso®, Yangzijiang Pharmaceuticals)
Description: For patients with AR, patients were given lupatadine fumarate (Luso®, Yangzijiang Pharmaceuticals) 1 tablet once daily at bedtime for 14 days.
Study: NCT06707467

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: occlusal splint
Description: nineteen patients diagnosed with internal temporomandibular derangement will receive occlusal splint therapy, a treatment method with proven effectiveness.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: occlusal splints combined with rocabado exercise
Description: Nineteen patients diagnosed with internal temporomandibular derangement will be provided with Rocabado exercises in addition to the proven-effective treatment method of occlusal splint therapy. This approach aims to evaluate whether Rocabado exercises have a positive effect on the treatment process.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: occlusal splint combined with posture exercise
Description: Nineteen patients diagnosed with internal temporomandibular derangement will be provided with posture exercises in addition to the proven-effective treatment method of occlusal splint therapy. This approach aims to evaluate whether posture exercises have a positive effect on the treatment process.
Study: NCT06705946

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aqua vest group
Description: Participants in this group will perform Dynamic Stability Training (DST) sessions twice a week for 12 weeks while wearing an aqua vest. Each session will focus on dynamic stability exercises aimed at improving balance, lower limb joint moment distribution, and gait. Each session will last for 50 minutes

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight vest group
Description: Participants in this group will perform the same Dynamic Stability Training (DST) sessions twice a week for 12 weeks, but with a weight vest instead of an aqua vest. Each session will focus on balance, lower limb joint moment distribution, and gait, lasting for 50 minutes
Study: NCT06708975

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Insulin therapy phonophoresis
Description: Insulin therapy phonophoresis is the use of ultrasound to deliver drugs through patients skin, Insulin therapy will be used to determine its effect on wound healing in patients with chronic diabetes mellites because in addition to its systemic impact, numerous reports suggest that applying insulin topically causes localized effects. Many trials and case reports have been released reporting positive effects of topical insulin for many diseases such as dermatological compromises, ophthalmological diseases and others

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperpolarized light therapy and Standard wound cleaning and dressing.
Description: Hyperpolarized light therapy safely accelerates wound healing by stimulating blood circulation, reducing inflammation and relieving muscle spasms.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Hyperpolarized light therapy and Standard wound cleaning and dressing.
Description: Hyperpolarized light therapy safely accelerates wound healing by stimulating blood circulation, reducing inflammation and relieving muscle spasms.
Study: NCT06710951

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Change of normal concentration of povidone-iodine 5% to 1%
Description: Normal concentration of povidone-iodine during anti-VEGF intravitreal injection was 5%. That concentration was utilized in the control group, and 1% in the experimental group.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Change of normal concentration of povidone-iodine 5% to 1%
Description: Normal concentration of povidone-iodine during anti-VEGF intravitreal injection was 5%. That concentration was utilized in the control group, and 1% in the experimental group.
Study: NCT06706596

Intervention type: OTHER
Intervention: Screening for TB symptoms
Description: Individuals will be screened for cough, blood in sputum, fever, weight loss, night sweats and chills lasting for \>2 weeks

Intervention type: DIAGNOSTIC_TEST
Intervention: Chest X-ray
Description: Chest X-ray will be performed to diagnose or exclude TB
Study: NCT06710301

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preliminary assessment
Description: Evaluation of the cognitive level through the Raven test and of spatial navigation skills through the Corsi test and the maze sub-test of the WISC-III.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Navigation task with EEG recording
Description: Administration of the navigation task in an immersive virtual reality environment and EEG signal recording. The participant will wear virtual reality viewers and EEG cap. The task consists in moving and orienting themselves inside a five-way maze in order to reach a treasure. The participant will be asked to carry out 30 trials lasting a maximum of 120s each.
Study: NCT06710496

Intervention type: OTHER
Intervention: analysis of medical records
Description: analysis of medical records of the patients
Study: NCT06707259

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD19 IL10 CAR-NK
Description: Lentiviral vector-transducted cord blood-derived NK cells to express anti-CD19-IL10 CAR
Study: NCT06737601

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: shock waves
Description: three sessions, weekly frequency
Study: NCT06735872

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non invasive ventilation (NIV)
Description: This group will receive a unique 10-minute session of non invasive ventilation with standard parameters directly on the CT table. The treatment will be delivered via a naso-buccal mask.~Prior to treatment, each participant will have a planned standard care chest CT.~During the session, a senior intensivist watching for participant's comfort and safety.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High flow oxygen therapy (HFO)
Description: This group will receive a unique 10-minute session of high flow oxygen directly on the CT table. The treatment will be delivered via a nasal cannula.~Prior to treatment, each participant will have a planned standard care chest CT.~During the session, a senior intensivist watching for participant's comfort and safety.
Study: NCT06742554

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine transdermal patch
Description: Buprenorphine Transdermal Patch (10 mg): Applied once before surgery for continuous pain control.~Interscalene Brachial Plexus Block: Administered intraoperatively using 25 mL of 0.5% bupivacaine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Tramadol: Administered orally or intravenously at a standard dose of 100 mg every 8 hours, based on patient-reported pain levels.~Interscalene Brachial Plexus Block: Administered intraoperatively using 25 mL of 0.5% bupivacaine.
Study: NCT06738407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline hyclate delayed released 200 mg
Description: 200 mg of doxycycline taken by mouth as soon as possible and within 72 hours after any condomless oral, vaginal/front hole, and/or anal sex.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline hyclate delayed released 200 mg weekly
Description: 200 mg of doxycycline taken by mouth weekly regardless of sexual activity
Study: NCT06744179

Intervention type: DIAGNOSTIC_TEST
Intervention: echocardiography, chest x-ray, full blood count , SGPT, lipid profile, HbA1C, AQ20 questionnaire, mmRC dyspnoea scale, Duke activity status index, COPD assessment test, Age and stage questionnaire
Description: Participants from both exposed and non-exposed groups will be assessed using different standardized questionnaire and a number of investigations to identify any cardiac and pulmonary complications over time. Individuals will be matched for age and sex to ensure comparability. This study aims to evaluate these complications and analyze any significant differences between the groups over the defined follow-up period.
Study: NCT06745180

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Short Message System (SMS)
Description: The Short Message System (SMS) intervention focuses on personalized, adaptive SMS messages that help the participant maintain physical activity behaviors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Coach
Description: The peer coach will deliver an intervention that will help participants maintain physical activity.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Care
Description: Participants will be given written materials providing advice on maintaining their physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Coach and SMS
Description: The Short Message System (SMS) intervention focuses on personalized, adaptive SMS messages that help the participant maintain physical activity behaviors. The peer coach will deliver an intervention that will help participants maintain physical activity.
Study: NCT06744933

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Self-administered auricular acupressure integrated with a smartphone application
Description: 6 to 8 Vaccariae Semen ear patches will be affixed on one ear of the patient. The patient will be required to press on the ear patches 3 times a day, and 30 minutes before a meal. Every 3 to 4 days, the patient will visit the clinic to change a new set of ear patches on the same auricular acupoints of the opposite ear alternately. The whole course of intervention will be 8 weeks. The smartphone app will send scheduled pop-up notifications to remind patients to press on the ear patches. The patient will be required to enter the number of times pressing and of defaecation every day on the smartphone application. The smartphone application will send more notifications to the patient if he/ she has a low compliance. When the participants record the number of times pressing on the auricular acupoints, positive reinforcement messages will pop-up, such as Excellent job! for those with good compliance while You are almost there! Keep going! for those with poor compliance.
Study: NCT06744166

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS-WAA
Description: Patients assigned to the TENS-WAA group will receive transcutaneous electrical nerve stimulation based on Wrist-Ankle Acupuncture theory for a duration of 30 minutes after anesthesia induction, as well as at 8 hours and 24 hours postoperatively. According to the principles of WAA, two pairs of TENS-WAA (Wuxi Jiajian Medical Device Co., Ltd.) electrode pads will be placed on the upper area 2 and 3 with the skin of the treatment area exposed, and the upper and lower juxtaposition method will be adopted. Upper area 2 is at the middle of the palmar side of the forearm, between the palmaris longus and flexor carpi radialis. Upper area 3 is between the edge of the radius and the radial artery. Stimulation parameters of TENS-WAA are alternating dense-disperse wave with a frequency of 2Hz and a pulse width of 200μs, and a frequency of 100Hz with a pulse width of 150μs, alternating every 3 seconds ，intensity required to reach the maximum tolerable level without causing pain.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham (No Treatment)
Description: Patients assigned to the sham TENS-WAA group will receive sham stimulation for a duration of 30 minutes after anesthesia induction, as well as at 8 hours and 24 hours postoperatively. Researchers will attach the electrode patches at the same location, set the parameters to the same frequency, pulse width, and minimum current intensity as the TENS-WAA group, but do not activate the device, leaving it in place for 30 minutes at each time point.
Study: NCT06313593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB160058
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB160058
Description: Oral; Tablet
Study: NCT06528873

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Concurrent optical and magnetic stimulation (COMS) treatment
Description: COMS treatment will be performed 2-3 times per week for at least 8 weeks, unless the wound heals sooner, with a minimum of 16 applications. Missed sessions can be made up in the 4-week follow-up period. Treatment will occur during standard care procedures, including dressing changes and debridement, and will follow these steps:~Remove old dressing Apply analgesic if necessary Perform debridement if necessary Cleanse the wound Apply COMS One device Apply new dressing Apply compression therapy as per study procedures (section 6.1)~If the patient is at home, a caregiver will perform this procedure. Study staff, including the PI, nurses, and caregivers, will receive training and a step-by-step document on using the COMS One device.
Study: NCT06067204

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automatic ventilation
Description: The FDA-approved device used is Meditech MICROVENT RESUSCITATOR, which is connected to the endotracheal tube, supraglottic airway or tracheostomy tube. It is powered by the airflow from the oxygen tank and provides ventilation in fixed interval. It has a pressure valve which will release the pressure once the airway pressure exceeds its threshold. In the current study, the threshold is set at 60 mmH2O. The tidal volume is set at 500-600 ml.
Study: NCT05385523

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General Anaesthesia
Description: Fentanyl (1 μg/kg), propofol (2-3mg/kg) and atracurium (0.3-0.5 mg/kg) will be injected intravenously 3-5 minutes after oxygenation. A single-lumen endotracheal tube will be used to complete ventilation. The ventilator ventilation mode is volume control mode, and the patient's end-expiratory carbon dioxide level is maintained at 35-40 mmHg throughout the anesthesia process. During the anesthesia maintenance phase, 2% sevoflurane mixed with 60% oxygen.~After general anaesthesia induction, all patients will receive RISS block with different local anesthetic drug mixture according to randomization.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General Anaesthesia
Description: Fentanyl (1 μg/kg), propofol (2-3mg/kg) and atracurium (0.3-0.5 mg/kg) will be injected intravenously 3-5 minutes after oxygenation. A single-lumen endotracheal tube will be used to complete ventilation. The ventilator ventilation mode is volume control mode, and the patient's end-expiratory carbon dioxide level is maintained at 35-40 mmHg throughout the anesthesia process. During the anesthesia maintenance phase, 2% sevoflurane mixed with 60% oxygen.~After general anaesthesia induction, all patients will receive RISS block with different local anesthetic drug mixture according to randomization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamedatomidine
Description: Patients will receive general anaesthesia and RISS block with 20 ml of 0.25% bupivacaine + 1 Mcg/kg dexamedatomidine in 2 mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Patients will receive general anaesthesia and RISS block with 20 ml of 0.25% bupivacaine + 8mg dexamethasone in 2 mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saline
Description: Patients will receive general anaesthesia and RISS block with 20 ml of 0.25% bupivacaine+ 2 mL normal saline.
Study: NCT05952375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chimeric antigen receptor T cell preparation targeting Claudin18.2
Description: Chimeric antigen receptor T cell preparation targeting Claudin18.2
Study: NCT06413875

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: education
Description: Education Specific to Menopause Symptoms
Study: NCT06569511

Intervention type: DIAGNOSTIC_TEST
Intervention: N-terminal pro-B-type natriuretic peptide (NT-proBNP)
Description: In patients diagnosed with Acute coronary syndrome, blood samples for serum NT-proBNP value were taken during transfer to the coronary intensive care unit

Intervention type: DIAGNOSTIC_TEST
Intervention: N-terminal pro-B-type natriuretic peptide (NT-proBNP)
Description: In patients diagnosed with Acute coronary syndrome, blood samples for serum NT-proBNP value were taken during transfer to the coronary intensive care unit

Intervention type: DIAGNOSTIC_TEST
Intervention: high sensitive cardiac troponin T (hs-cTnT)
Description: In patients diagnosed with Acute coronary syndrome, serum high-sensitive cardiac troponin T (hs-cTnT) levels were measured on admission to the Emergency Department.

Intervention type: DIAGNOSTIC_TEST
Intervention: high sensitive cardiac troponin T (hs-cTnT)
Description: In patients diagnosed with Acute coronary syndrome, serum high-sensitive cardiac troponin T (hs-cTnT) levels were measured on admission to the Emergency Department.
Study: NCT05301192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin-(1-7)
Description: This is a biologically active endogenous angiotensin peptide that may play an important role in regulation of blood pressure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline will be used as the placebo comparator.
Study: NCT04841148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCQ
Description: 600 mg tablets twice daily D1-28 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCQ
Description: 600 mg tablets twice daily D1-28 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: 10 mg/kg, IV, D1 and D15 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: 10 mg/kg, IV, D1 and D15 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: 125 mg capsule daily, by mouth on D1-21 concurrently with Avelumab. Or 75 mg capsule daily, by mouth on D1-28 concurrently with HCQ.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: 125 mg capsule daily, by mouth on D1-21 concurrently with Avelumab. Or 75 mg capsule daily, by mouth on D1-28 concurrently with HCQ.
Study: NCT05738096

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TSEPs recording only
Description: TSEPS will also be recorded from healthy controls in a lab setting; all procedures for the healthy controls will be non-invasive.
Study: NCT06405490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanoliposomal Irinotecan+Oxaliplatin +Capecitabine+Cadonilimab
Description: Use the above medications on a regular basis
Study: NCT06067204

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual ventilation
Description: The adult size bag-valve mask is connected to the endotracheal tube, supraglottic airway or tracheostomy tube. The interval, pressure and volume of the ventilation is controlled by the emergency medical technicians.